OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials

Dec 6, 2007

The Frost Group Invests $20 Million in OPKO Health

Dec 5, 2007

OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc.

Nov 29, 2007

OPKO Health Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections

Oct 30, 2007

OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye

Oct 10, 2007

OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors

Oct 1, 2007

OPKO Health to Present at UBS 2007 Global Life Sciences Conference

Sep 18, 2007

Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

Aug 30, 2007

Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost

Jul 12, 2007

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD

Jul 11, 2007